Beatrice Knudsen, MD, PhD

About Beatrice Knudsen, MD, PhD

Biomarkers of Response to Treatment with XL184 in the Bone
XL184 (caboxantanib) is a new experimental medication for metastatic prostate cancer with promising clinical results. To more effectively administer XL184 to patients with metastatic prostate cancer, Dr. Knudsen seeks to define the precise anti-cancer mechanism of action. She has assembled a team at Cedars-Sinai in Los Angeles and University of Washington/Fred Hutchinson Cancer Institute in Seattle to study the effects of XL184 in patient biopsies and will investigate the mechanism of action of this encouraging agent as a biomarker for response in patients.

Potential patient benefit: An understanding of the mechanism of action of XL184 will accelerate the clinical development of this very encouraging agent by providing investigators with laboratory and imaging biomarkers of response.

Award

The Susan and James Blair-PCF Creativity Award

Designation

Medical Director of Biorepository and Translational Pathology

University

Cedars-Sinai Medical Center